bm 13505 has been researched along with ridogrel in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cozzi, P; Ferrario, R; Giordani, A; Menichincheri, M; Pillan, A; Pinciroli, V; Rossi, A; Tamburin, M; Tonani, R; Volpi, D | 1 |
1 other study(ies) available for bm 13505 and ridogrel
Article | Year |
---|---|
Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Binding, Competitive; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Computer Simulation; Dogs; Fatty Acids, Unsaturated; Fibrinolytic Agents; Humans; Hydrazines; Imidazoles; Male; Models, Molecular; Molecular Structure; Pentanoic Acids; Platelet Aggregation; Prostaglandin Endoperoxides, Synthetic; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane; Stereoisomerism; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1994 |